http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2012078932-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5e129db6a59e07c6b34cf2b093fad5f5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c28ea23854cf9ddacd3821efe1d41462 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b6febfd932491c11ea29956d39fa8f8b |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2236-19 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K36-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-352 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-00 |
| filingDate | 2011-12-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_be8f4f1029c70d5b155a9628491dc90a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8a2c4fb38193a423319e17b6e87743c3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_34abed38cbc57921e57d800874cfc709 |
| publicationDate | 2012-06-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2012078932-A2 |
| titleOfInvention | Simultaneous co-treatment of physical and mental symptoms related to severe mental disorders by a specially fermented soy formulation (fsww08) |
| abstract | A method of treating severe mental diseases and related disorders or conditions includes administering to a patient in need thereof an effective amount of a composition including isoflavones and BBIF. Preferably, the composition is a fermented soy composition. Preferably, one first diagnoses a patient with a particular mental disease or disorder, and then prescribes the composition as a treatment for the particular mental disease or disorder. A patient is preferably given daily a dosage of 3-10 mg of isoflavones and 5-10 CI (chymotrypsin inhibitor) of Bowman Birk Inhibitory Factor per kg of body weight, more preferably a dosage of 5-9 mg of isoflavones and 5-10 CCI of Bowman Birk Inhibitory Factor per kg of body weight, and most preferably a dosage of 5-10 mg of isoflavones and 5-10 CCI of Bowman Birk Inhibitory Factor per kg of body weight. The doses of BBIC, Bowman Birk Inhibitory Concentrate, are measured in CI units, as described in detail elsewhere (Kennedy et al., 1993b); BBIC contains 100 mg/g CI activity, and, at most, 40 mg/g TI activity. FSWW08 contains the highest amount of BBIC measured in a product. This can be achieved by giving a patient daily 50ml-200ml of FSWW08, or about 1-3 ml of FSWW08 per kg of body weight. Treatment preferably lasts 7 days-14 days, or until all symptoms disappear. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-106947798-A |
| priorityDate | 2010-12-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 407.